EGFR and non-small cell lung carcinoma: The ADAURA trial reveals that daily dosing of osimertinib as adjuvant treatment in previously untreated EGFR mutation-positive NSCLC patients, with stage IB to IIIA, extends disease-free survival compared to patients in the placebo group [1].